Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 15;110(19):1433-1442.
doi: 10.1002/bdr2.1372. Epub 2018 Sep 10.

Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study

Affiliations

Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study

Sarah C Fisher et al. Birth Defects Res. .

Abstract

Background: There are limited data on the relationship between antihypertensive medication use in early pregnancy and risk of birth defects.

Methods: Using data from the National Birth Defects Prevention Study, we examined associations between specific antihypertensive medication classes and 28 noncardiac birth defects. We analyzed self-reported data on 17,038 case and 11,477 control pregnancies with estimated delivery dates during 1997-2011. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals, adjusted for maternal age, race/ethnicity, body mass index, parity, pregestational diabetes, and study site, for associations between individual birth defects and antihypertensive medication use during the first trimester of pregnancy. We compared risk among women reporting early pregnancy antihypertensive medication use to normotensive women.

Results: Hypertensive women who reported early pregnancy antihypertensive medication use were more likely to be at least 35 years old, non-Hispanic Black, obese, multiparous, and to report pregestational diabetes than normotensive women. Compared to normotensive women, early pregnancy antihypertensive medication use was associated with increased risk of small intestinal atresia (adjusted OR 2.4, 95% CI 1.2-4.7) and anencephaly (adjusted OR 1.9, 95% CI 1.0-3.5). Risk of these defects was not specific to any particular medication class.

Conclusions: Maternal antihypertensive medication use was not associated with the majority of birth defects we analyzed, but was associated with an increased risk for some birth defects. Because we cannot entirely rule out confounding by the underlying hypertension and most ORs were based on small numbers, the increased risks observed should be interpreted with caution.

Keywords: National Birth Defects Prevention Study; antihypertensive; birth defects; hypertension; pregnancy.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement: The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.
Reported type of hypertension among hypertensive pregnancies, by case/control and antihypertensive treatment status, NBDPS 2006-2011.

Similar articles

Cited by

References

    1. Banhidy F, Acs N, Puho EH, & Czeizel AE (2011a). Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res, 34(2), 257–263. doi:10.1038/hr.2010.227 - DOI - PubMed
    1. Banhidy F, Acs N, Puho EH, & Czeizel AE (2011b). Hypotension in pregnant women: a population-based case-control study of pregnancy complications and birth outcomes. Hypertens Res, 34(1), 55–61. doi:10.1038/hr.2010.172 - DOI - PubMed
    1. Bateman BT, Bansil P, Hernandez-Diaz S, Mhyre JM, Callaghan WM, & Kuklina EV (2012). Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol, 206(2), 134.e131–138. doi:10.1016/j.ajog.2011.10.878 - DOI - PMC - PubMed
    1. Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, … Hernandez-Diaz S (2015). Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol, 212(3), 337 e331–314. doi:10.1016/j.ajog.2014.09.031 - DOI - PMC - PubMed
    1. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Dejene SZ, … Huybrechts KF (2017). Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol, 129(1), 174–184. doi:10.1097/aog.0000000000001775 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources